Invokana Clinical Trials

Prescribing Information

Great Britain Northern Ireland

Key Studies

Click on a clinical study below:

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.

Perkovic V, Jardine MJ, Neal B, et al.

The New England Journal of Medicine 2019;380(24):2295-2306

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

Perkovic V, de Zeeuw D, Mahaffey KW, et al.
The Lancet Diabetes & Endocrinology 2018;6(9):691-704

Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.

Zaccardi F, Webb DR, Htike ZZ, et al.
Diabetes, Obesity & Metabolism 2016;18(8):783-794

Kidney disease and increased mortality risk in type 2 diabetes.

Afkarian M, Sacha M, Kestenbaum B, et al.
Journal of the American Society of Nephrology 2013;24(2):302-308

Invokana vs other SGLT2 inhibitors

Click on a clinical study below:

Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.

Zaccardi F, Webb DR, Htike ZZ, et al.
Diabetes, Obesity & Metabolism 2016;18(8):783-794

Cost of glycaemic target achievement with sodium glucose co-transporter-2 inhibitors in patients with type 2 diabetes in the UK.

Evans M, Achha S, Neslusan C, et al.

Diabetes Therapy 2017;8(5):1175-1185

A network meta-analysis to assess options for treatment intensification for patients with type 2 diabetes inadequately controlled on dual therapy.

Schroeder M, et al.
Diabetalogia 2015;58(Suppl1):S1-S607 Abstract 727

Consistent reductions in HbA1c with Invokana 100 mg and 300 mg

Click on a clinical study below:

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.

Lavalle-González FJ, Januszewicz A, Davidson J, et al.
Diabetologia 2013;56(12):2582-2592

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52 week randomized trial.

Schernthaner G, Gross JL, Rosenstock J, et al.
Diabetes Care 2013;36(9):2508-2515

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Stenlöf K, Cefalu WT, Kim KA, et al.
Diabetes, Obesity & Metabolism 2013;15(4):372-382

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

Forst T, Guthrie R, Goldenberg R, et al.
Diabetes, Obesity & Metabolism 2014;16(5):467-477

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.

Wilding JP, Charpentier G, Hollander P, et al.
International Journal of Clinical Practice 2013;67(12):1267-1282

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.

Cefalu WT, Leiter LA, Yoon KH, et al.
The Lancet 2013;382(9896):941-950

Invokana provides additional benefits of weight and blood pressure reduction

Click on a clinical study below:

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycaemic control with metformin plus sulfonylurea: a 52 week randomized trial.

Schernthaner G, Gross JL, Rosenstock J, et al.
Diabetes Care 2013;36(9):2508-2515

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Stenlöf K, Cefalu WT, Kim KA, et al.
Diabetes, Obesity & Metabolism 2013;15(4)372-382

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

Forst T, Guthrie R, Goldenberg R, et al.
Diabetes, Obesity & Metabolism 2014;16(5):467-477

Cefalu WT, Leiter LA, Yoon KH, et al.
The Lancet 2013;382(9896):941-950

Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose co-transporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.

Neal B, Perkovic V, de Zeeuw D, et al.
Diabetes care 2015;38(3):403-411

Safety and tolerability

Click on a clinical study below:

Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.

Usiskin K, Kline I, Fung A, et al.
Postgraduate Medicine 2014;126(3):16-34

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.

Nyirjesy P, Sobel JD, Fung A, et al.
Current Medical Research and Opinion 2014;30(6):1109-19

Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study.

Yuan Z, DeFalco F, Ryan PB, et al.
Diabetes, Obesity & Metabolism 2018;20(3):582-589

Support Materials

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyuk@napp.co.uk.